Specialty / Expertise

Genitorurinary cancers

Research Interests

Intermittent androgen suppression and the effects of androgen deprivation on the male mind and body

Current Research Projects

Research Staff

Training

Dr. Higano received her MD from University of Massachusetts Worcester, Massachusetts. She completed her Internal Medicine Residency at the Mayo Graduate School of Medicine, Rochester, Minnesota. She was a Post-Doctoral Fellow in Oncology at the University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA.

Selected Publications:

Wright JL, Higano CS, Lin DW. Intermittent androgen deprivation: Clinical experience and practical applications. Urol Clin North Am, 2006, 33:167-179.

Higano CS. Current status of treatment for patients with metastatic prostate cancer. Can J Urol 2005, 12 Suppl 2:38-41.

Higano CS. Counseling patients on choice of therapy: Medical Oncologist perspective. In Management of Prostate Cancer, E Klein (ed). Humana Press, 491-500, 2004.

Higano CS, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in prostate cancer patients without bone metastases who are treated with intermittent androgen suppression. Urology 2004, 64:1182-1186.

Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004, 100:592-899.

Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am, 2004, 31:331-352.

Higano CS. Androgen-deprivation therapy for prostate cancer. Clin Prostate Ca, 2003, 2:22-23.

Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003, 61(suppl 2A):32-38.

Higano CS. Management of bone loss in men with prostate cancer. J Urol 2003, 170:S59-S64.

Higano CS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol 2003, 21:392-398.